The next step toward identifying SIRPα-CD47 inhibiting SMs was to establish an assay that would enable us to test the ability of lead compounds to inhibit SIRPα binding to CD47 naturally expressed by tumor cells. The gene discussed is SIRPA; the disease is neoplasm.